Gout being sneaky🧐 Common consult question is "infection or flare?" in patients with gout. @ACR21 ABS0467 w/ Dr Michael Toprover: 🔸Calibrating DECT for LS-spine in gout patients. 🔹DECT signal = MSU deposition? 🔸Future data on back pain/gout flare/MSU🤞? @RheumaRepublic https://t.co/aDCusqBk8G

Important #gout study (I'm biased): allopurinol is non-inferior to febuxostat with regards to gout flare when used in a T2T approach, with no differences in AEs, including CV risk. 99% achieved serum urate target over course of trial. Key slides following. #ACR21 https://t.co/tWeGvZ4rKY

We may be getting a new urate lowering therapy. Tigulixostat is a non-purine selective xanthine oxidase inhibitor. Nothing worrying on safety. But I think febuxostat is probably more effective than this? Abstr#L05 #ACR21 @RheumNow https://t.co/Lg0slMlah2

Advantages of treat to target (of serum urate) beyond less gout flares? Maybe equal to ⬇️MACE events - I hope in long term less MACE due to less ⬆️CRP w flares. Modelling observational study abst#L06 #ACR21 #ACRBest @RheumNow below is comparative safety T2T better than usual care https://t.co/95M6lNX416

#ACR21 L05. Tigulixostat - non-purine selective XO inhibitor for gout ⭐️Effectively brought down serum uric acid <5, dose-dependent ⭐️10% pts gout flare with urate lowering @Rheumnow https://t.co/LgwkAQ1wg8 https://t.co/G8CxdGcVOQ

• https://bit.ly/2Yt45oD

#ACR21 L06 Comparative Safety of Gout "Treat-to-target" and "Usual Care" Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach https://t.co/4qo49lpBrt Video interview (https://t.co/k8PHCPaF1r) https://t.co/D4G2Ylkelm

• Comparative Safety of Gout &quot;Treat-to-target&quot; and &quot;Usual Care&quo…
• Kazuki Yoshida, ScD: Gout Treatment Strategies Regarding Cardiovascular Outcomes

8M415 Gout Imaging Advances: Ralf Thiele on US🔊and DECT US>DECT: DECT needs a minimal density of MSU; DCS, tophi <2mm, liquid tophi may not be detected; US can show hyperemia DECT>US: DECT can show areas that may be overlooked from standard protocols 💡Bonus:stay around for Q&A https://t.co/G7yQaj9fHw

Dr Stewart @TonyMerriman2 report in 16,000 patients that repeat serum urate testing not superior to single measure in predicting incident gout over 9 years. Makes sense in general, maybe different in those with medication changes etc? Abstr#1449 #ACR21 @RheumNow https://t.co/69NofMNuB8